BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ: BLSM · Real-Time Price · USD
13.50
+1.15 (9.31%)
At close: Nov 6, 2026, 4:00 PM EST
13.48
-0.02 (-0.15%)
After-hours: Nov 6, 2026, 7:30 PM EST
BlossomHill Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
BlossomHill presented strong phase I data for its lead EGFR inhibitor, showing high response rates and durability in C797S-resistant patients, with a favorable safety profile and differentiation from competitors. Key milestones include pivotal trial planning and new data readouts through 2027.